Guidelines on the management of common bile duct stones (CBDS)

E J Williams, J Green, I Beckingham, R Parks, D Martin and M Lombard

*Gut* 2008:57;1004-1021; originally published online 5 Mar 2008; doi:10.1136/gut.2007.121657

Updated information and services can be found at:
http://gut.bmj.com/cgi/content/full/57/7/1004

These include:

**References**
This article cites 235 articles, 38 of which can be accessed free at:
http://gut.bmj.com/cgi/content/full/57/7/1004#BIBL

**Open Access**
This article is free to access

**Email alerting service**
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

**Notes**

To order reprints of this article go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to *Gut* go to:
http://journals.bmj.com/subscriptions/
Guidelines on the management of common bile duct stones (CBDS)

E J Williams, J Green, I Beckingham, R Parks, D Martin, M Lombard

ABSTRACT
The last 30 years have seen major developments in the management of gallstone-related disease, which in the United States alone costs over 6 billion dollars per annum to treat. Endoscopic retrograde cholangiopancreatography (ERCP) has become a widely available and routine procedure, whilst open cholecystectomy has largely been replaced by a laparoscopic approach, which may or may not include laparoscopic exploration of the common bile duct (LCBDE). In addition, new imaging techniques such as magnetic resonance cholangiography (MR) and endoscopic ultrasound (EUS) offer the opportunity to accurately visualise the biliary system without instrumentation of the ducts. As a consequence clinicians are now faced with a number of potentially valid options for managing patients with suspected CBDS. It is with this in mind that the following guidelines have been written.

1.0 FOREWORD
This document, on the diagnosis and treatment of patients with common bile duct stones (CBDS), was commissioned by the British Society of Gastroenterology (BSG) as part of a wider initiative to develop guidelines for clinicians in several areas of clinical practice. Guidelines are not rigid protocols and they should not be construed as interfering with local clinical judgment. Hence they do not represent a directive of proscribed routes, but a basis on which clinicians can consider the options available more clearly.

2.0 INTRODUCTION AND OBJECTIVES
The last 30 years have seen major developments in the management of gallstone-related disease, which in the United States, alone, costs over 6 billion dollars per annum to treat. Endoscopic retrograde cholangiopancreatography (ERCP) has become a widely available and routine procedure, whilst open cholecystectomy has largely been replaced by a laparoscopic approach, which may or may not include laparoscopic exploration of the common bile duct (LCBDE). In addition new imaging techniques such as magnetic resonance cholangiography (MR) and endoscopic ultrasound (EUS) offer the opportunity to accurately visualise the biliary system without instrumentation of the ducts. As a consequence clinicians are now faced with a number of potentially valid options for managing patients with suspected CBDS. It is with this in mind that the following guidelines have been written.

3.0 FORMULATION OF GUIDELINES
Guidelines were commissioned by the British Society of Gastroenterology and have been endorsed by the Clinical Standards and Services Committee (CSSC) of the BSG, the BSG Endoscopy Committee, the ERCP stakeholder group, the Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS), Association of Laparoscopic Surgeons (ALS), and the Royal College of Radiologists (RCR). Contributions from all of these groups have been incorporated into the final version of the guideline document.

The method of formulation can be summarised as follows. In 2004 a preliminary literature search was performed by Earl Williams. Original papers were identified by a search of PubMed/Medline for articles containing the terms common bile duct stones, gallstones, choledocholithiasis, laparoscopic cholecystectomy or ERCP. Articles were first selected by title. Their relevance was then confirmed by review of the corresponding abstract. This initial enquiry focussed on full length reports of prospective design, though retrospective analyses and case reports were also retrieved if the topic they dealt with had not been addressed by prospective study. Missing articles were identified by manually searching the reference lists of retrieved papers.

A summary of the findings of this search was presented to the BSG Endoscopy Committee in 2004. Additional references were suggested and the principal clinical questions arising from the literature search agreed. Provisional guidelines were subsequently developed by a multi-disciplinary guideline writing group. This was comprised of representatives of the BSG (Earl Williams, Jonathan Green and Martin Lombard), AUGIS (Rowan Parks and Ian Beckingham), and RCR (Derrick Martin), Current British Society of Gastroenterology Guidelines, the European Association of Endoscopic Surgeons Guidelines on Common Bile Duct Stones, and the National Institute of Health’s “State of the Science” conference on ERCP were reviewed as part of this process. In 2006 an ERCP stakeholder group was convened and considered the provisional guidelines, with representatives of the BSG (Jonathan Green and Martin Lombard), AUGIS (Nick Hayes), ALS (Don Menzies) and RCR (Derrick Martin), along with the National Lead for Endoscopy (Roland Valori), all making contributions. Specifically, each recommendation was considered and amendments were suggested to ensure that, for all recommendations, consensus was achieved. The resulting statement
was then forwarded to the CSSC and GUT for comment and international peer review. Thereafter the final wording of the guideline document was agreed at a consensus meeting, held in 2007, where the document was again reviewed by the principal authors (Earl Williams, Jonathan Green, Rowan Parks, Martin Lombard and Derrick Martin), with each recommendation requiring a unanimous vote to be ratified.

3.1 Categories of evidence
The strength of the evidence used in these guidelines was that recommended by the North of England evidence-based guidelines development project. This is summarised below:

- **Ia**: Evidence from meta-analysis of randomised controlled trials (RCTs).
- **Ib**: Evidence from at least one randomised trial.
- **IIa**: Evidence from at least one well-designed controlled study without randomisation.
- **IIb**: Evidence obtained from at least one other type of well-designed quasi-experimental study.
- **III**: Evidence from well-designed non-experimental descriptive studies such as comparative studies, correlation studies, and case studies.
- **IV**: Evidence obtained from expert committee reports or opinions, or clinical experiences of respected authorities.

3.2 Grading of recommendations
Recommendations are based on the level of evidence presented in support and are graded accordingly.

**Grade A**: Requires at least one randomised controlled trial of good quality addressing the topic of recommendation.

**Grade B**: Requires the availability of clinical studies without randomisation on the topic.

**Grade C**: Requires evidence from category IV in the absence of directly applicable clinical studies.

4.0 SUMMARY OF RECOMMENDATIONS

4.1 General principles

4.1.1 Discussion of hepatobiliary cases in a multidisciplinary setting is to be encouraged. (Evidence grade IV. Recommendation grade C.)

4.1.2 It is recommended that wherever patients have symptoms, and investigation suggests ductal stones, extraction should be performed if possible. (Evidence grade III. Recommendation grade B.)

4.1.3 Trans-abdominal ultrasound scanning (USS) is recommended as a preliminary investigation for CBDS and can help identify patients who have a high likelihood of ductal stones. However, clinicians should not consider it a sensitive test for this condition. (Evidence grade III. Recommendation grade B.)

4.1.4 Where patients with suspected CBDS have not been previously investigated initial assessment should be based on clinical features, liver function tests (LFTs) and USS findings. (Evidence grade III. Recommendation grade B.)

4.1.5 EUS and MR are both recommended as being highly effective at confirming the presence of CBDS. When selecting between the two modalities patient suitability, accessibility and local expertise are the most important considerations. (Evidence grade IIb. Recommendation grade B.)

4.2 Endoscopic treatment

4.2.1 ERCP training programmes should follow the recommendations contained within current Joint Advisory Group (JAG) Guidelines. (Evidence grade IV. Recommendation grade C.)

4.2.2 It is important that once formal training is completed endoscopists perform an adequate number of biliary sphincterotomies (BS) per year to maintain their performance. As a guide 40–50 BS per endoscopist per annum is suggested. (Evidence grade III. Recommendation grade B.)

4.2.3 When performing endoscopic stone extraction (ESE) the endoscopist should have the support of a technician or radiologist who can assist in fluoroscopic screening, a nurse to manage the patient safely and an additional endoscopy assistant/nurse to manage guide wires etc. (Evidence grade IV. Recommendation grade C.)

4.2.4 It is recommended that ERCP be reserved for patients in whom the clinician is confident an intervention will be required. In patients with suspected CBDS it is not recommended for use solely as a diagnostic test. (Evidence grade IIb. Recommendation grade B.)

4.2.5 When scheduling ERCP the endoscopist needs to be aware of the patient-related factors that increase the risk of ERCP or BS-related complication. (Evidence grade III. Recommendation grade B.)

4.2.6 It is recommended that clinicians follow the BSG Guidelines on consent and use Department of Health forms (or their equivalent) to obtain written confirmation of consent. (Evidence grade IV. Recommendation grade C.)

4.2.7 Patients undergoing BS for ductal stones should have a FBC and PT/INR performed no more than 72 h prior to the procedure. It is recommended that where patients have deranged clotting subsequent management should conform to locally agreed guidelines. (Evidence grade III. Recommendation grade B.)

4.2.8 In patients established on anticoagulation therapy a local policy should be agreed for managing endoscopic stone extraction. For those at low risk of thromboembolism anticoagulants should be discontinued prior to endoscopic stone extraction if biliary sphincterotomy is planned. (Evidence grade III. Recommendation grade B.)

4.2.9 Biliary sphincterotomy can be safely performed on patients taking aspirin or non-steroidal anti-inflammatory drugs. Administration of low dose heparin should not be considered a contraindication to biliary sphincterotomy. (Evidence grade III. Recommendation grade B.)

4.2.10 Where possible, newer anti-platelet agents such as clopidogrel (Plavix) should be stopped 7–10 days prior to biliary sphincterotomy (Evidence grade IV. Recommendation grade C.)

4.2.11 Prophylactic antibiotics should be given to patients with biliary obstruction or previous features of biliary sepsis. (Evidence grade Ib. Recommendation grade A.) Patients should be managed in accordance with the BSG Guidelines on antibiotic prophylaxis during endoscopy (Evidence grade IV. Recommendation grade C.)

4.2.12 No drug is currently recommended for the routine prevention of pancreatitis among patients undergoing endoscopic stone extraction. (Evidence grade Ia. Recommendation grade A.)

4.2.13 Patients should be sedated and monitored in accordance with BSG Guidelines. (Evidence grade IV. Recommendation grade C.)

4.2.14 In patients with risk factors for post-ERCP pancreatitis, but not BS-induced haemorrhage, sphincterotomy initiated using pure cut may be preferable. (Evidence grade Ib. Recommendation grade A.)

4.2.15 Balloon dilation of the papilla (ED) can be an alternative to biliary sphincterotomy in some patients. However, the risk of (severe) post-ERCP pancreatitis is increased in comparison to BS and in the majority of patients undergoing...
4.3 Surgical treatment
4.3.1 An assessment of operative risk needs to be made prior to scheduling intervention. Where this risk is deemed prohibitive to the performance of any surgical technique, endoscopic retrograde cholangiopancreatography (ERCP) may be considered as an alternative. (Evidence grade III. Recommendation grade B.)

4.3.2 Intraoperative cholangiography (IOC) or laparoscopic ultrasound (LUS) can be used to detect common bile duct stones in patients who are suitable for surgical exploration or postoperative ERCP. Though not considered mandatory for all such patients, IOC is recommended for those who have an intermediate to high pre-test probability of CBDS and who have not had the diagnosis confirmed pre-operatively by other means. (Evidence grade IIIb. Recommendation grade B.)

4.3.3 In patients undergoing laparoscopic cholecystectomy (LCS), trans-cystic and trans-ductal exploration of the CBD are both recognised as appropriate techniques for removal of CBDS. (Evidence grade Ib. Recommendation grade B.)

4.3.4 When minimally invasive techniques fail to achieve duct clearance (open) surgical exploration remains an important treatment option. (Evidence grade III. Recommendation grade B.)

4.4 Supplementary treatments
4.4.1 It is recommended that all endoscopists performing ERCP should be able to supplement standard stone extraction techniques with mechanical lithotripsy when required. (Evidence grade III. Recommendation grade B.)

4.4.2 Where available, extra-corporeal shock wave lithotripsy (ESWL) can be considered for patients with difficult disease who are not fit enough/unwilling to undergo open surgery. Antibiotic prophylaxis during ESWL should be administered. (Evidence grade III. Recommendation grade B.)

4.4.3 Electro-hydraulic lithotripsy (EHL) and laser lithotripsy can effect duct clearance where other forms of lithotripsy have failed. (Evidence grade III. Recommendation grade B.)

4.4.4 Percutaneous treatment has been described as an alternative or adjunct to other forms of stone extraction. It is recommended that if facilities and expertise are available then its use should be considered when standard endoscopic and surgical treatment fails, or is considered inappropriate. (Evidence grade III. Recommendation grade B.)

4.4.5 Contact dissolution therapy is not recommended as treatment for CBDS. (Evidence grade III. Recommendation grade B.)

4.4.6 Where CBD stone size has precluded endoscopic duct clearance oral ursodeoxycholic acid may facilitate subsequent endoscopic retrieval. (Evidence grade IIa. Recommendation grade B.) Following successful duct clearance administration of long-term ursodeoxycholic acid may be considered. (Evidence grade Ib. Recommendation grade B.)

4.5 Management of specific clinical scenarios
4.5.1 Biliary sphincterotomy and endoscopic stone extraction (ESE) is recommended as the primary form of treatment for patients with CBDS post-cholecystectomy. (Evidence grade IV. Recommendation grade C.)

4.5.2 Cholecystectomy is recommended for all patients with CBDS and symptomatic gallbladder stones, unless there are specific reasons for considering surgery inappropriate (Evidence grade III. Recommendation grade B.)

4.5.3 Patients with CBDS undergoing laparoscopic cholecystectomy may be managed by laparoscopic common bile duct exploration (LCBDE) at the time of surgery, or undergo peri-operative ERCP. There is no evidence of a difference in efficacy, morbidity or mortality when these approaches are compared, though LCBDE is associated with a shorter hospital stay. It is recommended that the two approaches are considered equally valid treatment options, and that training of surgeons in LCBDE is to be encouraged. (Evidence grade Ib. Recommendation grade A.)

4.5.4 Where appropriate local facilities exist, those patients with (predicted) severe pancreatitis of suspected or proven biliary origin should undergo biliary sphincterotomy +/- endoscopic stone extraction within 72 h of presentation. (Evidence grade Ib. Recommendation grade B.)

4.5.5 It is recommended that non-jaundiced patients with mild biliary pancreatitis require supportive treatment only during the acute stage of their illness. (Evidence grade Ib. Recommendation grade A.) Where such patients undergo cholecystectomy this should be performed within 2 weeks of presentation. In this setting routine pre-operative ERCP is unnecessary, though MR cholangiography, IOC or laparoscopic ultrasound should be considered. (Evidence grade Ib. Recommendation grade A.)

4.5.6 Patients with acute cholangitis who fail to respond to antibiotic therapy or who have signs of septic shock require urgent biliary decompression. Biliary sphincterotomy, supplemented by stenting or stone extraction, is therefore indicated. Percutaneous drainage can be considered as an alternative to ERCP but open surgery should be avoided. (Evidence grade Ib. Recommendation grade A.)

4.5.7 In pregnant patients with symptomatic common bile duct stones, recommended treatment options include ERCP (with biliary sphincterotomy and endoscopic stone extraction) and LCBDE. (Evidence grade III. Recommendation grade B.)

5.0 NATURAL HISTORY OF GALLBLADDER STONES
Gallstones are present in approximately 15% of the United States population. Whilst figures quoted vary according to the age, sex and ethnicity of the group examined, the overall prevalence in the United Kingdom is likely to be similar. The majority of people with gallstones are unaware of their presence and over a 10-year period of follow-up only 15–26% of initially asymptomatic individuals will develop biliary
coli. However, the onset of pain heralds the beginning of recurrent symptoms in the majority of patients, and identifies those at risk of more serious complications. These include pancreatitis, cholecystitis and biliary obstruction. Over a 10-year period such complications can be expected to occur in 2–5% of patients with initially silent gallbladder stones.

It is these observations that provide the rationale for offering cholecystectomy to all patients with symptomatic gallstones, with the exception of those in whom surgical risk is considered prohibitive.

6.0 NATURAL HISTORY OF CBDS

It is recommended that wherever patients have symptoms, and investigation suggests ductal stones, extraction should be performed if possible. (Evidence grade III. Recommendation grade B.)

In Western countries CBDS typically originate in the gallbladder and migrate. Such secondary stones should be differentiated from primary CBDS that develop de novo in the biliary system. Primary stones are more common in south-east Asian populations, have a different composition to secondary stones, and may be a possible indicator for CBDS. When selecting between the two modalities patient suitability, accessibility and local expertise are the most important considerations. (Evidence grade IIIb. Recommendation grade B.)

Intraoperative cholangiography (IOC) and ERCP are generally considered to be the reference standards for diagnosis of CBDS. However, a diagnostic strategy based on routine instrumentation of the biliary system, particularly in patients who have a low pre-test probability of disease, is undesirable.

The following section examines the ability of trans-abdominal ultrasound, computed tomography, magnetic resonance imaging and endoscopic ultrasound to select patients with a high probability of CBDS. The role of such imaging prior to ERCP and surgery is discussed in sections 8.3 and 9.3. When comparing imaging modalities it should be borne in mind that even ERCP and IOC can occasionally miss small stones, particularly when non-dilute contrast is used.

Dilated CBD on USS 0.96 0.42 6.9 0.77

7.0 IDENTIFYING PATIENTS WITH PROBABLE CBDS

Trans-abdominal ultrasound scanning (USS) is recommended as a preliminary investigation for CBDS and can help identify patients who have a high likelihood of ductal stones. However, clinicians should not consider it a sensitive test for this condition. (Evidence grade III. Recommendation grade B.)

EUS and MR are both recommended as being highly effective for confirming the presence of CBDS. When selecting between the two modalities patient suitability, accessibility and local expertise are the most important considerations. (Evidence grade IIIb. Recommendation grade B.)

Intraoperative cholangiography (IOC) and ERCP are generally considered to be the reference standards for diagnosis of CBDS. However, a diagnostic strategy based on routine instrumentation of the biliary system, particularly in patients who have a low pre-test probability of disease, is undesirable.

The following section examines the ability of trans-abdominal ultrasound, computed tomography, magnetic resonance imaging and endoscopic ultrasound to select patients with a high probability of CBDS. The role of such imaging prior to ERCP and surgery is discussed in sections 8.3 and 9.3. When comparing imaging modalities it should be borne in mind that even ERCP and IOC can occasionally miss small stones, particularly when non-dilute contrast is used.

7.1 Trans-abdominal ultrasound scanning combined with clinical features

A number of specific trans-abdominal ultrasound scan (USS) and clinical findings, when present, have been shown to greatly increase the probability of stones being found in the CBD on further investigation. However, all suffer from low sensitivity, ie, the absence of such a finding does not infer the absence of CBDS (table 1). No one USS, biochemical or clinical finding can therefore be used in isolation as a predictive test for ductal stones. Rather clinicians should consider such variables in combination when deciding on whether a patient needs further investigation.

For example, in patients awaiting laparoscopic cholecystectomy the combination of age greater than 55 years, bilirubin greater than 30 μmol/l, and CBD dilatation on USS has been found to increase the probability of a CBD stone being found at ERCP to over 70% (fig. 1). Other predictive models based on combinations of clinical, biochemical and USS findings can similarly identify those at higher risk of harbouring CBDS.

<table>
<thead>
<tr>
<th>Indicator for CBDS</th>
<th>Specificity</th>
<th>Sensitivity</th>
<th>+ve likelihood ratio</th>
<th>−ve likelihood ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBDS on USS</td>
<td>1.00</td>
<td>0.3</td>
<td>13.6</td>
<td>0.70</td>
</tr>
<tr>
<td>Cholangitis</td>
<td>0.99</td>
<td>0.11</td>
<td>18.3</td>
<td>0.93</td>
</tr>
<tr>
<td>Pre-operative jaundice</td>
<td>0.97</td>
<td>0.36</td>
<td>10.1</td>
<td>0.69</td>
</tr>
<tr>
<td>Dilated CBD on USS</td>
<td>0.96</td>
<td>0.42</td>
<td>6.9</td>
<td>0.77</td>
</tr>
</tbody>
</table>

For example, in patients awaiting laparoscopic cholecystectomy the combination of age greater than 55 years, bilirubin greater than 30 μmol/l, and CBD dilatation on USS has been found to increase the probability of a CBD stone being found at ERCP to over 70% (fig. 1). Other predictive models based on combinations of clinical, biochemical and USS findings can similarly identify those at higher risk of harbouring CBDS.

Figure 1 Prediction of common bile duct stones in patients undergoing laparoscopic cholecystectomy. Derived from Barkun et al24 and other sources.
Conversely, in patients who have not had surgical exploration of the duct, the combination of both normal common bile duct on USS and normal liver function tests (LFTs) indicates a very low probability of bile duct stones (variably quoted as 0 to <5%).

### 7.2 Computerised tomography cholangiography

Studies in this area are heterogeneous, both in terms of computed tomography (CT) technique and reference standard. Specificities quoted for detection of CBDS vary between 84% (when performed without biliary contrast) and 100%. Sensitivities quoted in the same studies range from 65 to 93%. Where an independent reference standard is used ERCP appears the better of the two investigations. Where CT is compared with EUS (and ERCP or IOC is used as the reference standard) EUS appears a more sensitive test, particularly in patients with normal calibre common bile ducts and ductal stones less than 1 cm in diameter. Nonetheless, it should be noted that more recent studies suggest helical CT can diagnose CBDS with sensitivity and specificity that is comparable to MR cholangiography.

In conclusion then, the historic performance of CT cholangiography can only be considered fair when compared to ERCP or EUS, though more recent studies comparing CT to MR suggest it is a potentially useful test for CBDS.

### 7.3 Magnetic resonance imaging

Studies examining MR in comparison to ERCP have generally used ERCP as the reference standard. Such study designs do not allow the hypothesis that MR is superior to ERCP to be tested. In the majority of studies published to date MR has a sensitivity and specificity of 90% or more in relation to ERCP though a smaller number of studies suggest the sensitivity of MR in relation to ERCP is lower than this. In one study, where positive tests were then confirmed by surgical exploration, ERCP was demonstrated to have a sensitivity and specificity of 100% and MR a sensitivity of 91% with a specificity of 100%. This study also demonstrated that the sensitivity of MR fell from 100% for stones over 1 cm in diameter to 71% for stones less than 5 mm in diameter. Subsequent studies, using ERCP as the reference standard, have confirmed that the ability of MR to detect CBD stones, whilst generally good, is influenced by stone diameter. In addition to false negative results false positives are also recognised, particularly as a consequence of aerobilia. In a recent review of prospective studies Verma et al demonstrated MR, when compared to ERCP or IOC, had a sensitivity for CBDS of 0.85, and a specificity of 0.93.

It is likely therefore that MR cholangiography is almost as good as ERCP in the diagnosis of CBDS, though the ability of MR to consistently detect stones of a few millimetres in diameter has yet to be demonstrated. It should also be recognised that the presence of intracranial metallic clips, claustrophobia or morbid obesity might preclude MRCP. Nonetheless, given its increasing availability and accuracy, the European Association of Laparoscopic Surgeons now consider MR cholangiography to be the standard diagnostic test for CBDS.

### 7.4 Endoscopic ultrasound scanning

A dedicated echo-endoscope or US catheter probe can, when positioned in the duodenal bulb, give good images of the bile duct. CBDS appear as hyper-echoic foci when imaged with such a system. Several studies have compared EUS to ERCP as a diagnostic tool. Studies are generally small and involve patients with moderate to high risk of CBDS. Nonetheless, several use a gold standard of sphincterotomy and endoscopic bile duct exploration for positive cases, which allows the performance of ERCP and EUS to be compared.

Taken collectively the sensitivity of ERCP for CBDS in these studies ranges from 79 to 100% compared to 84–100% for EUS, and the specificity from 87 to 100% for ERCP compared to 96–100% for EUS. Neither test is consistently demonstrated to be superior when results of individual studies are examined.

In conclusion then, EUS appears comparable to ERCP as a diagnostic test for CBDS, and performs better than either USS or CT. Unlike ERCP, EUS does not require instrumentation of the sphincter of Oddi and does not subject patients to the associated risk of pancreatitis. With regards to MR, systematic review of prospective studies has failed to show a statistically significant difference in performance when the two modalities are compared, though for small CBD stones EUS may still be more sensitive. However, it should be noted that, unlike MR, EUS has yet to become widely available. In addition, it requires the patient to undergo endoscopy, does not provide images of the intra-hepatic ducts and may be difficult to perform on patients with altered gastric or duodenal anatomy.

### 8.0 ENDOCOPIC TREATMENT OF CBDS

Endoscopic retrograde cholangiopancreatography (ERCP) can be used to provide definitive or temporary treatment of CBDS. The following section discusses selection and preparation of patients for ERCP and compares available endoscopic techniques. The role of ERCP as an adjunct to surgery is discussed in section 11.0

### 8.1 Required facilities and personnel

ERCP training programmes should follow the recommendations contained within current Joint Advisory Group (JAG) Guidelines. (Evidence grade IV. Recommendation grade C.)

It is important that once formal training is completed endoscopists perform an adequate number of biliary sphincterotomies (BS) per year to maintain their performance. As a guide, 40–50 BS per endoscopist per annum is suggested. (Evidence grade III. Recommendation grade B.)

When performing endoscopic stone extraction (ESE) the endoscopist should have the support of a technician or radiologist who can assist in fluoroscopic screening, a nurse to monitor patient safety and an additional endoscopy assistant/nurse to manage guide wires etc. (Evidence grade IV. Recommendation grade C.)

North American data suggest at least 200 procedures are required before the average trainee can achieve selective cannulation rates in excess of 80%. For individuals trained in the UK the true figure is probably higher. It is therefore recommended that to both maintain and improve the quality of ERCP services training programmes adhere to current Joint Advisory Group Guidelines. Reports also suggest that complication rates for biliary sphincterotomy (BS) correlate with annual workload. As biliary sphincterotomy usually precedes endoscopic stone extraction (ESE) it is important that once formal training is completed endoscopists perform an adequate number of procedures per year to maintain their performance. As a guide a minimum of 40–50 BS per endoscopist per annum is suggested.
Table 2  Recognised complications of endoscopic retrograde cholangiopancreatography (ERCP)

<table>
<thead>
<tr>
<th>Complication</th>
<th>Incidence (%) reported by large-scale prospective studies*</th>
<th>References</th>
<th>Incidence (%) reported by BSG audit of ERCP†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-ERCP pancreatitis</td>
<td>1.3 to 6.7</td>
<td>67, 69, 70, 72, 74</td>
<td>1.5</td>
</tr>
<tr>
<td>Gastrointestinal haemorrhage</td>
<td>0.7 to 2</td>
<td>67, 69, 70, 72</td>
<td>0.9 (1.5% of BS patients)</td>
</tr>
<tr>
<td>Cholangitis</td>
<td>0.5 to 5</td>
<td>67, 69, 70, 72</td>
<td>1.1</td>
</tr>
<tr>
<td>Duodenal perforation</td>
<td>0.3 to 1</td>
<td>67, 69, 70, 72</td>
<td>0.4</td>
</tr>
<tr>
<td>Miscellaneous, including cardio-respiratory</td>
<td>0.5 to 2.3</td>
<td>67, 69, 70, 72</td>
<td>1.4</td>
</tr>
</tbody>
</table>

*Figures derived from consecutive biliary sphincterotomy (BS) patients and unselected series of diagnostic and therapeutic ERCP.
†Figures derived from all recorded procedures during the study period.

For successful ESE skilled nursing and radiography staff are essential. At a minimum the endoscopist requires the support of a technician or radiologist who can assist in fluoroscopic screening, a nurse to monitor patient safety and an additional endoscopy assistant/nurse to manage guide wires etc.

8.2 Selection of patients for ERCP

Discussion of cases in a multidisciplinary setting is to be encouraged. (Evidence grade IV. Recommendation grade C.)

When scheduling ERCP the endoscopist needs to be aware of the patient-related factors that increase the risk of an ERCP or BS related complication. (Evidence grade III. Recommendation grade B.)

Though a generally safe and effective procedure adverse events resulting from ERCP are well recognised. These are summarised in table 2.

The endoscopist should therefore be aware of the patient related factors that increase the risk of an ERCP or BS related complication. These include age less than 60–70 years,67–73 female sex,73 74 and a low probability of structural disease (as suggested by normal bilirubin, non-dilated ducts or suspected sphincter of Oddi dysfunction).67 69 71 73 74 Co-morbid conditions that may increase risk include cirrhosis,59 previous post-ERCP pancreatitis (PEP),67 73 and, when sphincterotomy is undertaken, coagulopathy.67 68 73 75

The risks for any one patient need also to be balanced against the likelihood of being able to offer treatment at the time of ERCP. Unnecessary biliary instrumentation should be avoided and it is recommended that ERCP be reserved for patients in whom the clinician is confident an intervention will be required. Appropriate investigation as described below is important. Discussion of cases in a multidisciplinary setting is to be encouraged.

8.3 Investigation of the CBD prior to ERCP

Where patients with suspected CBDS have not been previously investigated initial assessment should be based on clinical features, LFTs and USS findings. (Evidence grade III. Recommendation grade B.)

It is recommended that ERCP be reserved for patients in whom the clinician is confident an intervention will be required. In patients with suspected CBDS it is not recommended for use solely as a diagnostic test. (Evidence grade III. Recommendation grade B.)

Where patients have not been previously investigated initial assessment should be based on clinical features, LFTs and USS findings. Where initial assessment suggests a high probability of CBDS (see section 7.0), then it is reasonable to proceed directly to ERCP if this is considered the treatment of choice. This strategy is also likely to be cost effective.76

Where initial assessment suggests a low or uncertain index of suspicion for CBDS then it is recommended that patients undergo magnetic resonance imaging (MR) or endoscopic ultrasound (EUS), with ERCP reserved for those with abnormal or equivocal results. It should be noted that, in the absence of LFT abnormalities, a dilated CBD on USS does not reliably predict CBDS.59 In such cases it is more appropriate to perform an EUS or MR than proceed directly to ERCP.

8.4 Preparation of patients for ERCP

8.4.1 Consent

It is recommended that clinicians follow the BSG Guidelines on consent and use Department of Health forms (or their equivalent) to obtain written confirmation of consent. (Evidence grade IV. Recommendation grade C.)

Patients should receive verbal and preferably written information regarding ERCP prior to the procedure. The risks of ERCP and associated intended therapy should be explained. Patients should be aware of the risk of pancreatitis and a smaller risk of perforation or bleeding. Patients with obstructive jaundice and/or CBDS should also be made aware of the risk of cholangitis, which is an under-recognised cause of morbidity and mortality in UK practice.68 75 Whilst overall risk of pancreatitis is often quoted as approximately 5%, the likelihood of pancreatitis varies widely between different patient groups and as far as possible any discussion of risk should be individualised. Therapeutic alternatives should be discussed where appropriate. It is recommended that clinicians adhere to local policy in obtaining written confirmation of consent, and use the Department of Health Standard Consent Forms (or their equivalent).

8.4.2 Clotting and anticoagulation therapy

Patients undergoing BS for ductal stones should have a full blood count (FBC) and prothrombin time or international normalised ratio (PT/INR) performed no more than 72 h prior to the procedure. Where patients have deranged clotting subsequent management should conform to locally agreed guidelines. (Evidence grade III. Recommendation grade B.)

In patients established on anticoagulation therapy a local policy should be agreed for managing endoscopic stone extraction. For those at low risk of thromboembolism anticoagulants should be discontinued prior to ERCP if biliary sphincterotomy is planned. (Evidence grade III. Recommendation grade B.)

Biliary sphincterotomy can be safely performed on patients taking aspirin or non-steroidal anti-inflammatory drugs. Administration of
low dose heparin should not be considered a contraindication to BS. (Evidence grade III. Recommendation grade B.)

Where possible, newer anti-platelet agents such as clopidogrel (Plavix) should be stopped 7–10 days prior to BS (Evidence grade IV. Recommendation grade C.).

Abnormal clotting is a feature of both biliary obstruction and parenchymal liver disease. In prospective studies coagulopathy (variously defined as a platelet count less than 50 000 to 50 000/mm³, prothrombin time >2 s prolonged, or prothrombin test <50%), and conditions that predispose to it, such as ongoing haemodialysis, have been identified as risk factors for post-sphincterotomy haemorrhage.67 68 73 75 However, some retrospective studies have shown the incidence of post-sphincterotomy bleeding in patients with normal clotting parameters, including the patients with abnormal parameters which have been well corrected, is higher than in patients with abnormal haemostatic screens.60 74 As with percutaneous liver biopsy² the point at which abnormalities in coagulation become an absolute contra-indication to the procedure, and the affect of correcting abnormal laboratory parameters on outcome is difficult to determine from the available evidence.

Nonetheless, it is suggested that patients undergoing BS as part of treatment for CBDS have a full blood count and prothrombin time (or INR) performed within 72 h of the procedure, and that where patients have deranged clotting subsequent management should conform to locally agreed guidelines.

In patients receiving anti-coagulant therapy for a co-morbid condition an assessment of thrombo-embolic risk should be made. Where risk of thrombo-embolism is low (such as in patients with atrial fibrillation) anti-coagulants should be discontinued several days before biliary sphincterotomy. Whilst one study has suggested that resumption of anti-coagulation within 3 days of ERCP is a risk factor for post-sphincterotomy haemorrhage, data in this area are lacking, with many endoscopists routinely reintroducing anticoagulation earlier than this. In patients at higher risk of thrombo-embolic events the American Society for Gastrointestinal Endoscopy has indicated oral anticoagulation should be discontinued prior to biliary sphincterotomy and introduction of unfractionated IV heparin considered when INR becomes sub-therapeutic.80 Low molecular weight heparin has been discussed as an alternative to unfractionated heparin but it is important to be aware that data on its efficacy in this setting are lacking.81 In the absence of robust studies addressing this issue it is recommended that units develop their own locally agreed policy for managing stone extraction in patients on anticoagulation therapy.

ESE with or without biliary sphincterotomy can be safely performed on patients taking aspirin or non-steroidal anti-inflammatory drugs.67 75 76 Administration of low dose heparin has been reported to increase the risk of haemorrhage but also to lower post-ERCP pancreatitis (PEP) rates.67 73 On the basis of the most recent evidence heparin is unlikely to protect against pancreatitis.82 However, its use in low dose is not considered a contra-indication to ESE. Data on newer anti-platelet therapies are unavailable, but at present it is recommended that, wherever possible, drugs such as clopidogrel (Plavix) are discontinued 7–10 days prior to ESE.83

8.4.3 Antibiotic administration
Prophylactic antibiotics should be given to patients with biliary obstruction or previous features of biliary sepsis. (Evidence grade Ib. Recommendation grade A.) Patients should be managed in accordance with the BSG Guidelines on antibiotic prophylaxis during endoscopy (Evidence grade IV. Recommendation grade C.).

Routine administration of antibiotics to all patients undergoing ERCP is considered unnecessary, though this remains a debated issue.83 However, prophylactic antibiotics do reduce the risk of clinically significant sepsis in patients with biliary obstruction, or previous features of biliary sepsis.54 59 Antibiotics have also been recommended for patients with moderate to high-risk cardiac lesions, though unequivocal evidence of benefit is lacking. Where antibiotics are used oral ciprofloxacin or parenteral gentamicin, quinolone, cephalosporin or ureidopenicillin are recommended, and the British Society of Gastroenterology Guidelines on antibiotic prophylaxis during endoscopy should be followed.84

8.4.4 Pancreatitis prophylaxis
No drug is currently recommended for the routine prevention of pancreatitis among patients undergoing endoscopic stone extraction. (Evidence grade Ia. Recommendation grade A.)

More common than post-ERCP sepsis is post-ERCP pancreatitis (PEP). A wide range of drugs has been given to patients in an attempt to reduce the incidence of PEP.57 58 Results have generally been disappointing. Trans-dental or sub-lingual glycerol trinitrate (GTN) given prior to ERCP may reduce the incidence of PEP, but further study is required.89 In addition a recent multi-centre trial90 has generated renewed interest in using octreotide to prevent pancreatitis, but results are yet to be duplicated. Gabexate and somatostatin have also been suggested to reduce the incidence of PEP when administered as prolonged infusions peri-procedure.61 However, shorter term infusions of either drug, even in patients at high risk of PEP, are ineffective60 and a recently updated meta-analysis suggests no benefit with either agent.92

At present therefore no specific agent is recommended for routine PEP prophylaxis in patients undergoing endoscopic stone extraction.

8.4.5 Sedation, intravenous access and monitoring
Patients should be sedated and monitored in accordance with BSG Guidelines. (Evidence grade IV. Recommendation grade C.)

It is suggested that patients are sedated and monitored in accordance with BSG Guidelines.101 During ERCP falls in blood pressure can occur, and a large bore venous cannula is recommended. Patients with obstructive jaundice, who are fasted beforehand and may be drowsy for some hours afterwards, are at risk of dehydration and renal impairment, and should receive intravenous fluids. Their urine output should be monitored.

In many countries the use of propofol for sedation for ERCP is common practice. In addition, evidence from the United States suggests that nurses can be trained to safely deliver and monitor propofol-induced sedation.102 However, pending further recommendations from professional bodies within the UK propofol should not be used unless specialist anaesthetic support is available.

8.5 Biliary sphincterotomy and stone extraction
In patients with risk factors for post-ERCP pancreatitis, but not BS-induced haemorrhage, sphincterotomy initiated using pure cut may be preferable. (Evidence grade Ib. Recommendation grade A.)

Biliary sphincterotomy followed by stone extraction using a basket or balloon catheter represents standard endoscopic therapy for CBDS. Successful endoscopic treatment is possible
in the majority of patients and in skilled hands duct clearance can be achieved in over 90%, though in up to 25% of patients this requires two or more ERCPs.

In general, complications are those of ERCP, and in particular include post-sphincterotomy haemorrhage. Reported complication rates vary according to case mix, definitions used, and study design. Some form of adverse event following BS may occur in up to 10% of cases; though the incidence of severe complications is probably nearer 1–2% and rates of post-ERCP pancreatitis following stone extraction are low when compared to other indications for BS, such as sphincter of Oddi dysfunction. Death as a consequence of BS has been reported in 0.4% of cases. Late complications of BS include recurrent stone formation and cholangitis. For an individual patient such as after Bilroth II surgery, technically easier to perform in patients with altered anatomy.

8.6 Balloon dilation as an alternative to biliary sphincterotomy

Balloon dilation of the papilla (ED) can be an alternative to biliary sphincterotomy in some patients. However, the risk of (severe) post-ERCP pancreatitis is increased in comparison to BS and in the majority of patients undergoing stone extraction ED should be avoided (Evidence grade Ia. Recommendation grade A.).

Endoscopic balloon dilation of the papilla (ED) has been advocated as an alternative to endoscopic sphincterotomy in patients with gallstones. Finally, the procedure can be technically easier to perform in patients with altered anatomy such as after Billroth II surgery. However, several studies have suggested that in comparison to biliary sphincterotomy, ED may be a greater risk factor for PEP, a finding that has been recently confirmed by meta-analysis. Of particular concern is the preponderance of severe complications following ED in two of the published reports.

In conclusion, balloon dilation of the papilla can be an alternative to biliary sphincterotomy, and has been advocated in patients with coagulopathy or cirrhosis, where risk of post-sphincterotomy haemorrhage is increased. However, risk of (severe) PEP is increased in comparison to BS and in the majority of patients undergoing stone extraction ED should be avoided.

8.7 Biliary stenting for CBDS

It is important that endoscopists ensure adequate biliary drainage is achieved in patients with CBDS that have not been extracted. The short-term use of a biliary stent followed by further endoscopy or surgery is advocated. (Evidence grade III. Recommendation grade B.)

In contrast the use of a biliary stent as sole treatment for CBDS should be restricted to a selected group of patients with limited life expectancy and/or prohibitive surgical risk. (Evidence grade Ib. Recommendation grade A.)

Bacterial contamination of bile is a common finding in patients with CBDS and incomplete duct clearance may therefore place patients at risk of cholangitis. It is therefore important that endoscopists ensure adequate biliary drainage is achieved in patients with CBDS that cannot be retrieved. The short-term use of an endoscopic biliary stent followed by further ERCP or surgery has been shown to be a safe management option in this setting.

For patients over 70 years of age or with debilitating disease (as defined by the American Society of Anesthesiology) biliary stenting has also been examined as an alternative to ESE. The technique compares favourably with ESE in terms of immediate success and complication rate. However, at least a quarter of patients experience recurrent cholangitis during follow-up. Long-term results are probably more favourable in those patients without a gallbladder.

Therefore whilst biliary stenting as a “bridge” to further therapy is recommended, its use as definitive treatment for CBDS should be restricted to patients who have limited life expectancy or are judged by a surgeon to be at prohibitive surgical risk.

8.8 Role of pre-cut papillotomy

Multi-centre studies indicate pre-cut is a risk factor for complication. Therefore the procedure should be considered an advanced technique, to be employed only by those with appropriate training and experience. Its use should be restricted to those patients for whom subsequent endoscopic treatment is essential (Evidence grade III. Recommendation grade B.)

Deep biliary cannulation can be achieved by insertion of a bare wire or “needle knife” into the papillary orifice or by using a sphincterotome with a cutting wire that extends to the tip. When difficulties in biliary access are encountered “pre-cut” is used routinely by some endoscopists, but not by all. Reported complication rates following pre-cut range from 5 to 30%, Even when difficulty of cannulation is controlled for pre-cut remains a risk factor for PEP in most multi-centre studies and has been shown to be a risk factor for overall complication in the UK. However, data from advanced centres supports the supposition that pre-cut is no riskier than standard biliary sphincterotomy. Although the type
of pre-cut performed may influence outcome\textsuperscript{152} operator skill and experience would appear to be the most important determinant in explaining this variability. This underlines the need for selective, well-organised training in advanced endoscopy techniques if risks of ESE are to be minimised.

8.9 Role of prophylactic pancreatic stenting
Patients at high risk of post-ERCP pancreatitis (eg, because of prolonged cannulation and/or pre-cut) may benefit from short-term pancreatic stent placement. (Evidence grade Ib. Recommendation grade A.)

Post-ERCP pancreatitis may well arise as a result of impaired pancreatic drainage. Mechanical prophylaxis with a temporary pancreatic stent is of clear benefit in patients with suspected sphincter of Oddi dysfunction (SOD)\textsuperscript{147, 148} and may also have a role in patients undergoing endoscopic stone extraction. In particular it is recognised that difficult cannulation and pre-cut papillotomy are potentially valid indications.\textsuperscript{146-149} Pancreatic stenting can cause perforation and ductal injury and where a prophylactic stent is used most authorities recommend early removal if the stent fails to migrate spontaneously.\textsuperscript{147, 149, 150} This argues for the highest risk patients being referred to centres with appropriate experience in their management.

9.0 SURGICAL TREATMENT OF CBDS
Surgical treatment of CBDS occurs in the setting of concurrent laparoscopic cholecystectomy. This offers the opportunity to definitively treat gallstone related disease in a single stage procedure. However, as with ERCP, operator, patient and procedure-related factors all influence outcome. Surgical duct exploration as an alternative to ERCP is discussed in section 10.0.

9.1 Required facilities and personnel
Though in a minority of patients there remains an important requirement for open surgical treatment, laparoscopic cholecystectomy (LC) has superseded open cholecystectomy as the operation of choice for symptomatic gallstones.

Whilst over 80\% of gallbladders are now removed laparoscopically the more recently developed technique of laparoscopic common bile duct exploration (LCBDE) has yet to become as widely available. LCBDE requires a flexible choledochoscope together with light source and camera, and disposable instrumentation similar to that required for ERCP (eg, baskets, balloons, stents). In contrast, open bile duct exploration can be carried out without a choledochoscope, significantly reducing capital outlay costs. However, blind instrumentation of the bile duct is not encouraged given that it may increase the risk of post-choledochotomy stricture formation.

There is significant learning curve for laparoscopic bile duct surgery both amongst surgeons and nursing staff.\textsuperscript{151} Given that the current provision of non-implant hepatobiliary services in the UK is almost certainly insufficient, manpower issues will need to be addressed to ensure the country has adequate numbers of appropriately trained surgeons in the future.\textsuperscript{152}

9.2 Selection of patients for surgical bile duct exploration
An assessment of operative risk needs to be made prior to scheduling intervention. Where this risk is deemed prohibitive endoscopic therapy should be considered as an alternative. (Evidence grade III. Recommendation grade B.)

Laparoscopic surgical exploration of the bile duct allows for single stage treatment of gallstone disease with removal of the gallbladder as part of the same procedure. This may reduce overall hospital stay when compared to the two-stage approach of ERCP and laparoscopic cholecystectomy.\textsuperscript{153, 154} The additional complications of surgical duct exploration are predominantly related to choledochotomy ( bile duct leakage) and T-tube use ( bile leakage, tube displacement). Pancreatitis is rare unless there has been ante-grade instrumentation of the papilla.\textsuperscript{155}

T-tubes were traditionally inserted in open bile duct exploration because of the risk of bile leakage from the choledochotomy, which arose as a result of uncertainty regarding duct clearance (in the absence of choledochoscopy), or because of the presence of oedema and inflammation as a result of blind instrumentation of the duct. LCBDE with optical magnification, direct visualisation and more delicate instrumentation allows reduced trauma to the bile duct and has resulted in an increasing tendency to close the duct primarily. This avoids the morbidity associated with T-tubes, and necessity for T-tube cholangiograms, though as yet there is no conclusive data favouring one technique over the other.\textsuperscript{156}

Systematic review of studies reporting the outcome of LCBDE reveals morbidity rates of between 2 and 17\% and mortality rates of 1–5\%.\textsuperscript{155} This is comparable to ERCP, with a recent Cochrane review\textsuperscript{156} of randomised control studies concluding that there was no clear difference in primary success rates, morbidity or mortality between the two approaches. However, it should be noted that populations in such studies have by definition been selected as fit for surgery. Therefore drawing conclusions regarding risks of LCBDE compared to alternative treatment in elderly and frail patients is difficult.

What is known is that in patients over 70–80 years of age mortality rates associated with open duct exploration are around 4–10\%, and may be as high as 20\% where elderly patients are subjected to urgent procedures.\textsuperscript{153–157} These findings contrast with ERCP, where advanced age and co-morbidity do not appear to have a significant impact on overall complication rates.\textsuperscript{158–161}

Therefore, as with any surgical intervention, an assessment of operative risk needs to be made. Where this risk is deemed prohibitive endoscopic therapy should be considered as an alternative.

9.3 Investigation of the CBD prior to surgical exploration
Intraoperative cholangiography (IOC) or laparoscopic ultrasound (LUS) can be used to detect CBDS in patients who are suitable for surgical exploration or postoperative ERCP. Though not considered mandatory for all such patients, IOC is recommended for those patients who have an intermediate to high pre-test probability of CBDS and who have not had the diagnosis confirmed preoperatively by other means. (Evidence grade III. Recommendation grade B.)

The standard way of imaging the CBD intraoperatively is by trans-cystic cannulation of the CBD with a fine catheter and direct injection of non-ionic contrast into the bile duct. Plain x ray plates have largely been superseded by image intensification, which reduces positioning failure, allows real-time imaging of the ducts (aiding the assessment of stones), and reduces procedural time and radiation dosage. As a test for ductal stones laparoscopic IOC has a quoted sensitivity of 80–92.8\% and specificity of 76.2–97\%.\textsuperscript{151, 162} More recently intraoperative laparoscopic ultrasound (LUS) has been found to be as sensitive as, and faster than, IOC. It also avoids the hazards of radiation to staff and patients.\textsuperscript{163, 164}

Whether all patients undergoing cholecystectomy need to undergo IOC has been extensively debated in the literature. Routine IOC has been advocated on two grounds. First, it accurately defines anatomy and may therefore allow surgeons
to minimise the risk of ductal injury, or at a least take prompt remedial action when such injury occurs.\textsuperscript{106–110} Second, it may detect asymptomatic ductal stones.\textsuperscript{106–110}

Conversely, a policy of selective IOC has been argued to minimise unnecessary biliary instrumentation. Moreover, recent studies of MRCP and EUS have demonstrated preoperative findings that are concordant with IOC results, suggesting that such tests can also be effective in screening for CBDs.\textsuperscript{114–116} However, the cost of performing such preoperative imaging on all patients would be high, and the availability of specialised imaging techniques is very variable throughout the country. The use of preoperative results to select patients for further imaging is therefore considered a permissible strategy, although it is recognised that some clinicians may opt to perform an IOC in all patients undergoing cholecystectomy. As already discussed in section 7.1 patients with normal preoperative LFTs and a normal diameter CHD/CBD on ultrasound have a very low chance of a CBD stone. Further imaging is not considered mandatory in this group. However, patients who are clinically jaundiced should undergo preoperative ERCP or, alternatively, MRCP (to exclude malignant disease) followed by single stage LCBDE/OCBDE. Which strategy should be adopted will largely depend on local availability of surgical and endoscopic skills. In centres not performing LCBD, non-jaundiced patients with a dilated CBD or abnormal LFTs should undergo a pre-cholecystectomy MRCP or EUS to identify CBD stones, which are present in around 10%. Patients with CBD stones can then be offered preoperative ERCP followed by LC or single stage OCBDE. An alternative to preoperative imaging in this group of patients is to perform IOC with conversion to OCBDE or postoperative ERCP if CBD stones are found. Centres performing high volumes of LCBD will require very few patients with a low to intermediate probability of CBDs to be imaged preoperatively, instead proceeding directly to laparoscopy with IOC or LUS to identify those patients who require laparoscopic exploration to remove CBDs.

9.4 Technical considerations of CBDs

It is recommended that in patients undergoing laparoscopic cholecystectomy trans-cystic or trans-ductal exploration of the CBD is an appropriate technique for CBDs removal. (Evidence grade II. Recommendation grade A.)

Laparoscopic cholecystectomy is the treatment of choice for symptomatic gallstones and is associated with short hospital stays and minimal morbidity.\textsuperscript{171, 172} The uptake of LCBD has, however, been less rapid as compared to the uptake of LC. In part this is because the technique requires significant capital outlay and is technically difficult, requiring endoscopic skills and laparoscopic suturing skills. It is estimated that only 20% of bile duct explorations are performed laparoscopically at the present time, with findings from a 2005 survey of English hospitals suggesting fewer than one in three units treat patients using this technique.\textsuperscript{175} As discussed in section 8.2 use of T-tubes, and increasing age appear to increase risk of complication for LCBD.\textsuperscript{174, 176} Nonetheless the procedure compares favourably with an open approach and preserves the benefits associated with LC.\textsuperscript{151, 176, 177}

Laparoscopic exploration may involve a trans-cystic or trans-ductal approach. The trans-cystic approach is more limited allowing retrieval of only small stones and poor access to the CHD. It can be performed under image intensifier control or with the use of an ultra-thin choledochoscope (8 mm). The majority of surgeons use the trans-ductal approach directly through the CBD. Regardless of exact technique LCBD has been demonstrated to be an effective treatment for CBDs, with reported rates of duct clearance comparable to those obtained with pre- or postoperative ERCP.\textsuperscript{103, 113, 114, 176–179} Long-term results also appear favourable.\textsuperscript{109, 110} It is therefore recommended that, in patients undergoing laparoscopic cholecystectomy, trans-cystic or trans-ductal exploration of the CBD is an appropriate technique for CBDs removal.

10.0 MANAGEMENT OF “DIFFICULT” STONE DISEASE

When minimally invasive techniques fail to achieve duct clearance (open) surgical exploration remains an important treatment option. (Evidence grade III. Recommendation grade B.)

Extraction of ductal stones via an endoscopic biliary sphincterotomy or laparoscopic route may be difficult or inappropriate for a variety of reasons. Most obviously size, shape and number of stones may make extraction difficult, but in addition patients may have stones that lie proximal to a biliary stricture. In addition to open surgical exploration of the duct, which retains an important role in the management of very difficult stone disease, a variety of other techniques may be employed, and these are described below.

10.1 Mechanical lithotripsy

It is recommended that all endoscopists performing ERCP should be able to supplement standard stone extraction techniques with mechanical lithotripsy when required. (Evidence grade III. Recommendation grade B.)

Mechanical lithotripsy is an endoscopic technique that involves trapping stones within a reinforced basket, after which a spiral sheath is cranked down onto the ensnared stone to crush and fragment it. Mechanical lithotripsy is successful in over 80% of cases where standard balloon or basket extraction cannot be performed, though duct clearance is less likely to be achieved where a stone is impacted in the bile duct.\textsuperscript{180–183} Stone size may also be important in predicting success though reports are conflicting.\textsuperscript{185–188}

Because it requires the same basic skills as “standard” endoscopic stone extraction and can be performed as part of the same procedure it is an attractive option for large CBD stones. It is recommended that all endoscopists performing ERCP should be able to supplement biliary sphincterotomy and standard stone extraction techniques with mechanical lithotripsy when required. Emergency “over the basket” lithotripsy is still occasionally required when a standard basket engages a large stone and becomes impacted, and it is therefore essential that units have the equipment available to perform this.

10.2 Extra-corporeal shock wave lithotripsy

Where available extra-corporeal shock wave lithotripsy (ESWL) can be considered for patients with difficult disease who are not fit enough/unwilling to undergo open surgery. Antibiotic prophylaxis during ESWL should be administered. (Evidence grade III. Recommendation grade B.)

Extra-corporeal shock wave lithotripsy (ESWL) uses electro-hydraulic or electro-magnetic energy to fragment CBDs. Insertion of a naso-biliary drain is performed to allow fluoroscopic identification and targeting of CBDs. Direct visualisation and/or manipulation of the stone are unnecessary. Patients are usually sedated for treatment, which typically takes up to 90 min to perform. The energy setting and number of discharges delivered varies according to the device used and patient tolerance. Cholangiography the following day identifies
those patients in whom treatment has been successful. Further courses of ESWL can be administered if necessary and residual fragments may be removed by ERCP. Kidney lithotripters can be used and results using a variety of devices and protocols have been reported, with typical rates of duct clearance ranging between 60 and 90\%.

The main adverse effects specific to ESWL are pain, local haematoma formation, and haematuria, which usually resolve without specific treatment. More seriously, cholangitis is a recognised sequela of treatment and may occur more frequently in patients who do not receive antibiotic prophylaxis. It is recognised that very few units have access to ESWL and that it is rarely indicated for CBDS. However, where available its use should be considered when routine endoscopic techniques, including mechanical lithotripsy, fail to achieve duct clearance and the patient is unfit or unwilling to undergo surgery. Antibiotic prophylaxis during treatment should be administered.

10.3 Intra-corporeal electro-hydraulic and laser lithotripsy

Electro-hydraulic lithotripsy (EHL) and laser lithotripsy can effect duct clearance where other forms of lithotripsy have failed. (Evidence grade III. Recommendation grade B.)

These techniques involve delivering energy directly to a large or impacted stone using a per-oral laser fibre or electro-hydraulic lithotripsy (EHL) probe. Continuous irrigation of the CBD is required and whilst stone recognition systems have been developed which allow laser therapy to be performed under fluoroscopic guidance treatment generally involves direct visualisation of the stone using a choledochoscope. Compared to the other forms of lithotripsy described the numbers treated to date using these techniques are small. However, in skilled hands rates of duct clearance are high and in randomised control trials have exceeded those achieved with ESWL. Electro-hydraulic lithotripsy is also used in laparoscopic bile duct exploration to deal with large or impacted stones and can improve duct clearance rates to >95\%. It is therefore recognised that EHL and laser lithotripsy can effect duct clearance where other forms of lithotripsy have failed.

10.4 Percutaneous radiological treatment

Percutaneous access to the biliary system can be obtained using an established T-tube tract or introducer sheaths via the liver or gallbladder. Where a preceding ERCP has failed and biliary obstruction persists the immediate imperative will be to provide adequate biliary drainage and this may be temporarily achieved by use of an internal stent or internal/external biliary drain. Percutaneous cholangiography can also provide useful diagnostic information at the same time.

However, the interventional radiologist may also push ductal stones into the duodenum or (rarely) retrieve stones percutaneously. The exact technique employed can vary and may involve use of a basket, electro-hydraulic lithotripsy, laser lithotripsy, ante-grade sphincterotomy or balloon dilation. The creation and dilation of a trans-hepatic fistula is more invasive than endoscopy and can be time consuming. Nonetheless high success rates are reported and the technique may be attractive in situations where a retrograde approach is impossible (eg, CBDS proximal to a tight stricture).

In addition where endoscopic access to the papilla is difficult, eg, in patients who have a long afferent jejunal loop following abdominal surgery, the radiologist may assist the endoscopist in performing a retrograde BS by feeding a guide-wire through the papilla and into the duodenum. Such combined procedures are more likely to result in a complication when compared to BS achieved by ERCP alone, with one multivariate analysis reporting an adjusted odds ratio of 3.4 (confidence interval, 1.04 to 11.13). Given that percutaneous treatment involves considerable discomfort to the patient it should not be considered a first-line therapy for CBDS. However, it is recommended that when other methods of stone extraction fail or are impossible percutaneous treatment can be considered as an alternative or adjunct to ERCP and surgery. In the absence of comparative trials the choice of percutaneous technique should be decided on the basis of local expertise.

10.5 Dissolution therapy

Contact dissolution therapy is not recommended as treatment for CBDS. (Evidence grade III. Recommendation grade B.)

Where CBD stone size has precluded endoscopic duct clearance oral ursodeoxycholic acid may facilitate subsequent endoscopic retrieval. (Evidence grade IIa. Recommendation grade B.) Following successful duct clearance administration of long-term ursodeoxycholic acid may be considered. (Evidence grade Ib. Recommendation grade B.)

Chemicals infused into the biliary system via a T-tube or naso-biliary drain can cause complete or partial dissolution of stones. In the latter case stones may then be removed by standard endoscopic techniques. Treatments using monooctanoin, methyl tert-butyl ether (MBTE) and 1% EDTA/bile acid solution have been tried. Diarrhoea is a common side effect of monooctanoin and MBTE may cause drowsiness, biliary strictures, cardiac arrhythmias, LFT abnormalities and duodenitis. Given the seriousness and frequency of complications, and that results to date suggest no more than 50% of patients benefit from such treatment contact dissolution therapy has been abandoned as a treatment modality for CBDS. It is not recommended under any circumstance.

In the UK ursodeoxycholic acid at a dose of 8–12 mg/kg daily is licensed as a treatment for gallstones. Whilst there is no evidence that ursodeoxycholic acid reduces biliary symptoms in patients awaiting cholecystectomy it may have a role in reducing the size of CBD stones which would otherwise be irretrievable endoscopically. To be effective treatment usually needs to be administered for several months.

Ursodeoxycholic acid at a dose of 500 mg/day has been shown to reduce the risk of stones forming in the gallbladder when given to patients undergoing obesity surgery. Whether the drug has a role in the prevention of CBDS formation following duct clearance is less clear. In a randomised control trial of patients who had undergone endoscopic stone removal 1 in 22 ursodeoxycholic acid treated patients developed a CBDS after some 19 months of follow-up, whereas four of 26 patients receiving placebo had developed recurrent stones by approximately 16 months. More evidence is required to advocate the routine prescription of ursodeoxycholic acid following stone extraction, though secondary prevention with the drug may be considered in selected cases.

11.0 MANAGEMENT OF CBDS IN SPECIFIC CLINICAL SETTINGS

In discussing the management of probable or definite CBDS it is helpful to consider the following clinical settings. In cases of...
“difficult” stone disease any of the treatment options described below may need to be supplemented by the techniques described in section 10.0:

11.1 CBDS and no gallbladder
BS and endoscopic stone extraction (ESE) is recommended as the primary form of treatment for patients with CBDS post-cholecystectomy. (Evidence grade IV. Recommendation grade C.)

The minimally invasive nature of ERCP has ensured that BS in association with endoscopic stone extraction has become the primary form of treatment for this group of patients. This approach is advocated, though it should be noted there are no trials directly comparing endoscopic stone extraction (ESE) with surgical stone extraction in this setting.

11.2 CBDS and in situ gallbladder
In this setting the clinician needs to consider both stone extraction and gallbladder removal. A number of potentially valid treatment options have evolved and these are described below. The management of gallstone pancreatitis and acute cholangitis are also considered separately in sections 11.3 and 11.4.

11.2.1 Endoscopic stone extraction without subsequent gallbladder removal
Cholecystectomy is recommended for all patients with CBDS and symptomatic gallbladder stones, unless there are specific reasons for considering surgery inappropriate (Evidence grade III. Recommendation grade B.)

In patients with CBDS cholecystectomy may be performed routinely or reserved for those who develop recurrent biliary symptoms following ESE. Randomised control studies comparing these two approaches suggest 15–37% of patients whose gallbladder is left in situ will develop symptoms that require cholecystectomy during a follow-up period ranging from an average of 17 months to over 5 years. Recurrent symptoms following ESE are most likely to be reported by younger, surgically fit patients with radiologically proven gallstones. Deferred laparoscopic cholecystectomy in this group is associated with higher rates of conversion to open surgery and a greater risk of surgical complication.

In addition, whilst gallbladder cancer is rare it should be noted that a policy of routine cholecystectomy for patients with secondary CBDS, particularly in the elderly, would both prevent and treat early disease.

Therefore in patients with CBDS and gallstones ESE as sole treatment should be avoided unless there are patient related factors that make cholecystectomy inappropriate.

It should be noted that the management of CBDS in patients with empty gallbladders is less clear. Large scale prospective follow-up of such patients in Japan suggests that, following successful ESE, there is a low rate of recurrent bile duct stones, a low risk of cholecystitis and no occurrence of gallbladder cancer. Such a study has yet to be performed in a European population. However, it is likely that, regardless of race, gallstones form an independent risk factor for recurrent symptoms following ESE.

11.2.2 Open cholecystectomy and common bile duct exploration
In the pre-laparoscopic era routine ERCP prior to open surgery was found to be broadly comparable to a single stage approach of open cholecystectomy and bile duct exploration. However, for the reasons discussed in section 9.0, laparoscopic cholecystectomy (LC) has replaced open cholecystectomy as the reference standard for treatment of gallbladder stones. As a first line, open surgical management of common bile duct stones has therefore been largely superseded by the minimally invasive management options described below. Nonetheless, as recommended in section 10.0, OCBDE remains an important technique for managing bile duct stones that are unsuitable for endoscopic treatment or that are unable to be removed at ERCP. Open exploration may be superseded by LCBDE as this technique becomes more widely available, even in the absence of RCTs showing a major benefit.

11.2.3 Laparoscopic cholecystectomy with endoscopic stone extraction (ESE) or laparoscopic common bile duct exploration (LCBDE)
Patients with CBDS undergoing laparoscopic cholecystectomy may be managed by laparoscopic common bile duct exploration (LCBDE) at the time of surgery, or undergo peri-operative ERCP. There is no evidence of a difference in efficacy, morbidity or mortality when these approaches are compared, though LCBDE is associated with a shorter hospital stay. It is recommended that the two approaches are considered equally valid treatment options, and that training of surgeons in LCBDE is to be encouraged. (Evidence grade Ib. Recommendation grade A.)

In deciding to perform an ERCP in conjunction with LC the clinician can choose to routinely or selectively endoscope patients before surgery. Alternatively he/she can perform postoperative (or, more rarely, intraoperative) ERCP on patients with a positive intraoperative cholangiogram.

Given that only a minority of patients undergoing LC are likely to have bile duct stones identified, indiscriminate use of preoperative ERCP is not recommended. Selecting patients on the basis of jaundice or abdominal ultrasound/computertised tomography scanning increases the likelihood of identifying bile duct stones at ERCP to around 50%. Using this approach <5% of patients with CBDS are predicted to be missed prior to surgery. However, the highest yield is obtained when patients undergo ERCP on the basis of a positive IOC. Under such circumstances >70% of ERCPs performed will identify CBDS.

On the basis of these observations selective postoperative ERCP is more cost effective than selective preoperative ERCP. However, the analyses upon which this conclusion is based did not incorporate the use of newer imaging modalities such as MR and EUS, which can improve the overall likelihood of stones being found to over 90%. Use of these additional imaging techniques is likely therefore to render the two approaches equivalent, as discussed in section 9.3.

In randomised control trials the outcomes associated with LC plus LCBDE are comparable with those of LC plus selective ESE. This applies irrespective of whether ESE is performed preoperatively or postoperatively. A single stage procedure incorporating LCBDE may be associated with shorter hospital stays and an argument for a single stage laparoscopic approach has also been made on grounds of cost effectiveness. However, given that LCBDE does not appear superior to a dual stage procedure in terms of efficacy, morbidity or mortality the most important considerations when deciding on treatment for an individual patient are local availability and expertise.

11.3 Acute biliary pancreatitis
Where appropriate local facilities exist, those patients with (predicted) severe pancreatitis of suspected or proven biliary origin should undergo biliary sphincterotomy +/- endoscopic stone extraction within 72 h of presentation. (Evidence grade Ib. Recommendation grade B.)
It is recommended that non-jaundiced patients with mild biliary pancreatitis require supportive treatment only during the acute stage of their illness. (Evidence grade Ib. Recommendation grade A.) Where such patients undergo cholecystectomy this should be performed within 2 weeks of presentation. In this setting routine preoperative ERCP is unnecessary, though MR cholangiography, IOC or laparoscopic ultrasound should be considered. (Evidence grade Ib. Recommendation grade A.)

Common bile duct stones are a recognised cause of acute pancreatitis. A biliary aetiology for pancreatitis may be suggested by liver function test abnormalities; the presence of gallbladder stones, ductal stones or bile duct dilatation on imaging; or co-existent cholangitis. In such cases the timing and selection of patients for ESE is important. The following recommendations are aligned with current UK Guidelines on the management of acute pancreatitis, which are available at the BSG website (www.bsg.org.uk). They do not supplant these guidelines, or any subsequent update of them.

First, where patients have jaundice, cholangitis or (predicted) severe disease of biliary aetiology \cite{224, 225} BS plus ESE within 72 h of presentation is recommended. When compared to delayed ESE this approach has been shown to reduce morbidity and may also reduce mortality in the subgroup of patients with severe pancreatitis and biliary obstruction. \cite{226, 227}

In patients with (predicted) mild pancreatitis and normal or only mildly elevated serum bilirubin levels, it has been clearly shown that ERCP has no role, with one randomised control trial suggesting an increase in complication rate, \cite{228} two suggesting no benefit \cite{229, 230} and one published in abstract form suggesting improvement. \cite{231} Meta-analysis of these trials suggests early ESE for unselected cases of biliary pancreatitis will save one life for every 26 patients treated. \cite{232} However, this conclusion appears to be misleading given the heterogeneity of the studies described. Furthermore, a conservative approach to mild pancreatitis is supported by observations that 80% of patients with mild biliary pancreatitis pass stones spontaneously \cite{233} and that it is uncommon to find ductal stones in this group at ERCP. \cite{234} It is therefore recommended that non-jaundiced patients with mild biliary pancreatitis require supportive treatment only during the acute stage of their illness. Where such patients undergo cholecystectomy this should be performed within 2 weeks of presentation. Routine preoperative ERCP is unnecessary. \cite{235, 236} Some very recent reports, which only came to light as these guidelines went to press, seem to support the view that only patients with acute pancreatitis who also have cholangitis will benefit specifically from emergency sphincterotomy and that perhaps early intervention in patients with pancreatitis but no cholangitis is not advantageous (Petrov, accepted for publication).

11.4 Acute cholangitis

Patients with acute cholangitis who fail to respond to antibiotic therapy or who have signs of septic shock require urgent biliary decompression. Biliary sphincterotomy, supplemented by stenting or stone extraction, is therefore indicated. Radiographically guided percutaneous drainage can be considered as an alternative to ERCP but open surgery should be avoided. (Evidence grade Ib. Recommendation grade A.)

The majority of patients with calculous cholangitis have mild to moderate disease, which responds to antibiotics. In such circumstances endoscopic and/or surgical management can be planned on an elective basis. However, a minority have signs of severe sepsis and, overall, 15–30% of patients with bacterial cholangitis fail to respond to antibiotic therapy. \cite{237} Such patients require urgent biliary decompression. Where bile duct stones are identified endoscopic biliary sphincterotomy and stone extraction is treatment of choice with reported success rates of over 90% and mortality rates of 4–10%. \cite{238, 239} It should be noted that for patients with pus within the bile duct many clinicians advocate stenting \cite{240} as initial therapy, to avoid prolonged ERCP times and minimise complication rates of the procedure. Open surgery in this group is associated with a considerably higher mortality than ERCP and should be avoided. \cite{241, 242} It is recognised that in circumstances where ERCP fails or is unavailable percutaneous biliary drainage has a role.

A minority of patients with gallstones and severe cholangitis have an empty common bile duct at the time of ERCP. Mortality in this group is low when compared to patients with a retained stone. Hui et al. \cite{243} have reported that whilst BS shortens duration of both fever and hospital stay in such patients, it does not influence the incidence of recurrent cholangitis. Nonetheless, given that small stones can be missed on cholangiography, BS followed by balloon or basket trolley of the duct is recommended for all cholangitis patients that require emergency ERCP.

11.5 CBDS in pregnancy

In pregnant patients with symptomatic CBDS, recommended treatment options include ERCP (with biliary sphincterotomy and endoscopic stone extraction) and LCBDDE. (Evidence grade III. Recommendation grade B.)

Little has been published in this area. However, a review of case series and individual reports suggest that BS is a safe and effective treatment for CBDS in the pregnant patient. \cite{244, 245} The foetus should be appropriately shielded and it is important that the endoscopist keeps radiation exposure to a minimum, which can be achieved by limiting fluoroscopy time and taking “screen grabs” rather than hard copies of ERCP images. To minimise the risk of aspiration arising from gastro-oesophageal reflux, women in the 2nd or 3rd trimester of pregnancy should have ERCP performed under general anaesthesia with endotracheal intubation.
intubation. It should be remembered that in late pregnancy the supine position can induce severe hypotension and must be avoided. Successful laparoscopic cholecystectomy and stone clearance has also been reported in pregnant patients\(^ {25-26} \) and may be considered in units where the technique is available. It should be noted that there is insufficient data to draw firm conclusions about the efficacy of surgery versus endoscopy.

12.0 ACKNOWLEDGEMENTS

The writing group would also like to acknowledge the comments and suggestions of Nick Hayes, Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS); Don Menzies, Association of Laparoscopic Surgeons of Great Britain and Ireland (ALS); Kel Palmer, previous chair of both the Joint Advisory Group on Gastrointestinal Endoscopy (JAG) and BSG Endoscopy Committee; Duncan Loft, on behalf of the BSG Clinical Standards and Services Committee; and Roland Valori, National Endoscopy Lead.

Competing interests: None.

REFERENCES


